Research Desk Line-up: Peregrine Pharma Post Earnings Coverage

LONDON, UK / ACCESSWIRE / September 20, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Mesoblast Ltd (NASDAQ: MESO), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=MESO, following the Company's release of its financial results for the fourth quarter fiscal 2017 (Q4 FY17) and full year fiscal 2017 (FY17) on August 30, 2017. The Melbourne, Australia-based Company reported net loss for the reported quarter and full year FY17. Our daily stock reports are accessible for free, and with those to look forward today you also will be signing up for a complimentary member's account at:

http://protraderdaily.com/register/

Get more of our free earnings reports coverage from other constituents of the Biotechnology industry. Pro-TD has currently selected Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) for due-diligence and potential coverage as the Company announced on September 11, 2017, its financial results for Q1 FY18 which ended on July 31, 2017, and also provided an update on its contract manufacturing operations, research and development programs, and other corporate highlights. Register for a free membership today, and be among the early birds that get access to our report on Peregrine Pharma when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on MESO; also brushing on PPHM. With the links below you can directly download the report of your stock of interest free of charge at:

http://protraderdaily.com/optin/?symbol=MESO

http://protraderdaily.com/optin/?symbol=PPHM

Earnings Reviewed

Mesoblast reported total revenue of $0.57 million in Q4 FY17 compared to $26.88 million recorded in Q4 FY16. The Company reported a non-cash decline of $26.31 in its revenues during Q4 FY17, primarily due to a significant deferred revenue item of $22.5 million being recognized in Q4 FY16.

The developer of cell-based medicines posted loss attributable to the owners of Mesoblast of $27.18 million, or $6.40 loss per diluted share, in Q4 FY17 versus profit attributable to the owners of Mesoblast of $48.29 million, or $12.78 per diluted share, in Q4 FY16. Meanwhile, the Company reported total comprehensive loss attributable to the owners of Mesoblast of $27.15 million in Q4 FY17 versus comprehensive income attributable to the owners of Mesoblast of $47.72 million in Q4 FY16.

In FY17, Mesoblast's total revenue came in at $2.41 million compared to $42.55 million in the previous year. The Company reported loss attributable to the owners of Mesoblast of $76.82 million, or $19.43 loss per diluted share, in FY17, versus loss attributable to the owners of Mesoblast of $4.13 million, or $1.14 loss per diluted share, in FY16. Furthermore, the Company's total comprehensive loss attributable to the owners of Mesoblast during FY17 was $76.47 million compared to total comprehensive loss attributable to the owners of Mesoblast of $5.17 million in FY16.

Operating Metrics

In Q4 FY17, the Company spent $15.94 million on research and development (R&D) expenses, compared to $14.40 million in Q4 FY16. Mesoblast's manufacturing commercialization expenses was $1.15 million in Q4 FY17 from $7.72 million in the prior year's same period. Furthermore, the Company loss before income tax narrowed to $31.26 million in Q4 FY17 from loss before income tax of $34.21 million in Q4 FY16.

Cash Flow and Balance Sheet

In year ended June 30, 2017, net cash outflows in operating activities increased to $95.47 million from net cash outflows in operating activities of $88.00 million in FY16. As on June 30, 2017, the Company had cash and cash equivalents balance of $45.76 million compared to a balance of $80.94 million as on June 30, 2016.

Entitlement Offer

On September 15, 2017, the Company announced that it had successfully completed the fully underwritten 1 for 12 pro-rata accelerated non-renounceable entitlement offer raising approximately A$50.7 million. Furthermore, the company had cash reserves of $84.0 million on a pro-forma basis as of June 30, 2017.

Stock Performance

On Tuesday, September 19, 2017, the stock closed the trading session at $5.46, climbing 1.11% from its previous closing price of $5.40. A total volume of 9.31 thousand shares have exchanged hands. Mesoblast's stock price rallied 16.17% in the previous twelve months. Furthermore, since the start of the year, shares of the Company have gained 2.06%. At Tuesday's closing price, the stock's net capitalization stands at $514.55 million.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily